<DOC>
	<DOCNO>NCT01221870</DOCNO>
	<brief_summary>The intravenously administer taxane , paclitaxel , one commonly employed agent treatment localize advanced breast cancer . Tesetaxel orally administer taxane development first- second-line treatment patient advance cancer . This study undertaken determine efficacy safety tesetaxel administer first-line therapy patient metastatic breast cancer .</brief_summary>
	<brief_title>Tesetaxel First-line Therapy Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Primary Female At least 18 year age Histologically cytologically confirm adenocarcinoma breast Stage IV disease HER2 status negative Measurable disease ( revised RECIST ; Version 1.1 ) Eastern Cooperative Oncology Group performance status 0 1 Life expectancy least 3 month Chemotherapy na√Øve 1 prior chemotherapy regimen adjuvant setting ( Prior taxanebased adjuvant therapy allow provided patient diseasefree interval least 12 month complete adjuvant therapy ) Prior hormonal therapy , aromatase inhibitor therapy , immunotherapy allow Prior radiotherapy adjuvant set allow provide less 25 % bone marrow irradiate Adequate bone marrow , hepatic , renal function , specify protocol At least 4 week recovery effect prior surgery , hormonal therapy , aromatase inhibitor therapy , immunotherapy , radiotherapy , therapy approve investigational agent Ability swallow oral soliddosage form medication Primary Known metastasis central nervous system History malignancy within last 5 year curatively treat basal squamous cell carcinoma skin carcinoma cervix situ Significant medical disease Stage IV breast cancer Presence neuropathy &gt; Grade 1 ( NCI CTC , Version 4.0 ) History hypersensitivity taxane Need continue regularlytaken medication potent inhibitor inducer CYP3A pathway Pglycoprotein activity</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>First-line therapy</keyword>
	<keyword>Tesetaxel</keyword>
	<keyword>Oral taxane</keyword>
</DOC>